C07K 2317/40
Characterized by post-translational modification
Official title: characterized by post-translational modification
C07K2317/40 (Characterized by post-translational modification) appears on 1,795 US grants and 3,584 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,795
- Published applications
- 3,584
- Assignees
- 965
- Inventors
- 5,690
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 4 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 1 |
| 2002 | 1 | 10 |
| 2003 | 2 | 14 |
| 2004 | 6 | 29 |
| 2005 | 4 | 31 |
| 2006 | 1 | 47 |
| 2007 | 2 | 59 |
| 2008 | 9 | 49 |
| 2009 | 16 | 70 |
| 2010 | 36 | 91 |
| 2011 | 39 | 98 |
| 2012 | 52 | 119 |
| 2013 | 74 | 114 |
| 2014 | 79 | 175 |
| 2015 | 102 | 200 |
| 2016 | 103 | 232 |
| 2017 | 138 | 230 |
| 2018 | 113 | 197 |
| 2019 | 156 | 235 |
| 2020 | 142 | 254 |
| 2021 | 134 | 226 |
| 2022 | 105 | 237 |
| 2023 | 125 | 215 |
| 2024 | 132 | 251 |
| 2025 | 138 | 244 |
| 2026 | 72 | 156 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-CCR8 antibodies for treating cancer29 Sep 2026US 12,747,296 B2Bristol-Myers Squibb Company
- Epithelial cadherin-specific antibodies15 Sep 2026US 12,735,498 B2Kling Biotherapeutics B.V.
- Antibodies that bind to human chemokine (C-C motif) receptor 8 (CCR8)8 Sep 2026US 12,729,241 B2Gilead Sciences, Inc.
- Humanized antibodies directed against KCNK91 Sep 2026US 12,723,075 B2Kennedy Krieger Institute, Inc.
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308247 A1Novartis AG
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308248 A1Novartis AG
- Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor8 Oct 2026US 2026/0308257 A1Agenus Inc.
- Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases8 Oct 2026US 2026/0308261 A1Konkuk University Industrial Cooperation Corp.
- Anti-psma antibodies and uses thereof8 Oct 2026US 2026/0308273 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells237US 6,187,287 B1Immunomedics, Inc. · 2001